Duality Biotherapeutics, Inc. (HKG:9606)
Hong Kong
· Delayed Price · Currency is HKD 277.80
-2.20 (-0.79%)
Apr 29, 2026, 4:08 PM HKT
Duality Biotherapeutics Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
| Cash & Equivalents | 1,276 | 1,209 | 1,131 |
| Short-Term Investments | 1,998 | 188.06 | 5.26 |
| Trading Asset Securities | 99.14 | - | - |
| Cash & Short-Term Investments | 3,374 | 1,397 | 1,136 |
| Cash Growth | 141.52% | 22.96% | - |
| Accounts Receivable | 277.92 | 379.02 | 100.8 |
| Other Receivables | 37.86 | 70.44 | 32.55 |
| Receivables | 315.78 | 449.46 | 133.35 |
| Prepaid Expenses | 59.15 | - | - |
| Restricted Cash | 49.71 | 45.16 | 42.65 |
| Other Current Assets | 35.56 | 18.26 | 21.75 |
| Total Current Assets | 3,834 | 1,910 | 1,334 |
| Property, Plant & Equipment | 28.68 | 18.6 | 17.76 |
| Other Intangible Assets | 3.77 | 46.24 | 54.25 |
| Other Long-Term Assets | 26.28 | 115.56 | 94.01 |
| Total Assets | 3,893 | 2,090 | 1,500 |
| Accounts Payable | 761.94 | 670.91 | 234.81 |
| Accrued Expenses | - | 38.97 | 25.24 |
| Short-Term Debt | 141.06 | - | - |
| Current Portion of Leases | 4.81 | 2.99 | 2.91 |
| Current Income Taxes Payable | - | 1.72 | 0.92 |
| Current Unearned Revenue | 77.77 | 90.26 | 156.13 |
| Other Current Liabilities | 66.29 | 3,067 | 2,141 |
| Total Current Liabilities | 1,052 | 3,872 | 2,561 |
| Long-Term Leases | 3.91 | 2.3 | 2.41 |
| Long-Term Unearned Revenue | 240.92 | 238.25 | 60.16 |
| Other Long-Term Liabilities | 169.53 | - | - |
| Total Liabilities | 1,466 | 4,112 | 2,624 |
| Common Stock | 0.06 | 0.01 | 0.01 |
| Retained Earnings | -4,855 | -2,161 | -1,111 |
| Comprehensive Income & Other | 7,281 | 133.26 | -19.2 |
| Total Common Equity | 2,427 | -2,028 | -1,130 |
| Shareholders' Equity | 2,427 | -2,022 | -1,124 |
| Total Liabilities & Equity | 3,893 | 2,090 | 1,500 |
| Total Debt | 149.78 | 5.29 | 5.32 |
| Net Cash (Debt) | 3,224 | 1,392 | 1,131 |
| Net Cash Growth | 131.68% | 23.07% | - |
| Net Cash Per Share | 49.48 | 173.96 | 141.35 |
| Filing Date Shares Outstanding | 88.61 | 8 | 8 |
| Total Common Shares Outstanding | 88.61 | 8 | 8 |
| Working Capital | 2,782 | -1,962 | -1,227 |
| Book Value Per Share | 27.39 | -253.46 | -141.22 |
| Tangible Book Value | 2,423 | -2,074 | -1,184 |
| Tangible Book Value Per Share | 27.34 | -259.24 | -148.00 |
| Machinery | - | 10.74 | 7.61 |
| Construction In Progress | - | 0.55 | 0.19 |
| Leasehold Improvements | - | 6.92 | 6.33 |
Source: S&P Capital IQ. Standard template. Financial Sources.